Request Demo

Last update 16 Jun 2025

Cannabinoids

Last update 16 Jun 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cannabinoids, Orthocann, ReneCann

+ [10]

Target

A3R

Action

agonists

Mechanism

A3R agonists(Adenosine A3 receptor agonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesCongenital Disorders+ [8]

Active Indication

Osteoarthritis, KneeDermatitis, AtopicPsoriasis+ [14]

Inactive Indication

Staphylococcal Infections

Originator Organization

Can-Fite BioPharma Ltd.

Active Organization

Curtin University

Universidad Complutense de Madrid

Avextra Pharma GmbH

+ [10]

Inactive Organization

NEVIS BRANDS, INC. /US/

University of Mississippi

Skye Bioscience, Inc.

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with Cannabinoids

ACTRN12622000419763

/ Not yet recruitingPhase 2IIT

The CANnabinoids in CANcer (CANCAN) trial: Investigating the effect of medicinal cannabis on symptoms and side effects of chemotherapy in people with cancer

Start Date01 Feb 2025

Sponsor / Collaborator

Central Adelaide Local Health Network, Inc.

ChiCTR2400094082

/ SuspendedNot ApplicableIIT

Investigation of the clinical features of synthetic cannabinoid drug users

Start Date01 Jan 2025

Sponsor / Collaborator-

DRKS00034785

/ RecruitingNot ApplicableIIT

Experiences of patients with chronic non-tumor pain undergoing cannabinoid therapy - a qualitative analysis - CANQUAL

Start Date11 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cannabinoids

100 Translational Medicine associated with Cannabinoids

100 Patents (Medical) associated with Cannabinoids

8,670

Literatures (Medical) associated with Cannabinoids

31 Dec 2025·Journal of Immunotoxicology

Immunotoxicological disruption of pregnancy as a new research area in immunotoxicology

Review

Author: Nakamura, Kazuichi

Immune mechanisms associated with normal pregnancy have only been being substantively investigated since the early 1990s. In parallel with the progress in that area of research, in the past few years it has become increasingly clear that several xenobiotics - including a variety of environmental chemicals, pharmaceuticals, and metals are considered to be both generally immunotoxic and specifically able to affect pregnancy. Among these, there is intense interest regarding potential effects from synthetic cannabinoids, immune checkpoint inhibitors, nanometals, and microplastics, with immunotoxic events that impact on pregnancy being shown for these agents. For instance, phytocannabinoids have been shown to interfere with reproduction in mice through effects on the endocannabinoid system. Because of effects of immune enhancement, as a requirement for regulatory submission, co-inhibitory immune checkpoint molecule inhibitors were also evaluated for effects on pregnancy. Similarly, because of increasing use and concerns about incidental environmental exposures, nanometals, and micro-plastics have also been examined for effects. Several studies in humans or mice showed that exposures to each during gestation increased the risk/rate of fetal loss, in part, by disruption of the placenta-associated immune system. Furthermore, signaling by endogenous danger molecules and/or impairment of physiological intercellular mediators may have contributed to the pregnancy loss. As there are clearly a variety of immunotoxic effects that can impact on a pregnancy, this review attempts to briefly introduce immune mechanisms associated with pregnancy as well as reasons for its loss, and proposes that 'immunotoxicological disruption of pregnancy' be accepted as a new research area in immunotoxicology.

01 Dec 2025·Current gastroenterology reports

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

Review

Author: Schneider, Yecheskel ; Rollins, Samantha ; Dzwonkowski, Monica ; Bahirwani, Janak ; Muratore, Alicia ; Christian, Vikram

PURPOSE OF REVIEW:

Inflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients.

RECENT FINDINGS:

In this review, we present several studied herbal therapies for the management of both Crohn's disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions. In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD.

01 Nov 2025·TALANTA

Molecularly imprinted polymers for illicit drug detection: A review of computational and synthesis methods

Review

Author: Khan, Sabir ; Neres, Lariel Chagas da Silva ; Zeb, Shakeel ; Sotomayor, Maria Del Pilar Taboada ; Calvo-Marzal, Percy

This review discusses the current state of molecularly imprinted polymers (MIPs) used for drug extraction and quantification. It begins with an introduction to MIP synthesis techniques that utilize illegal drugs as templates. The subsequent sections explore applications, focusing on the detection of illegal narcotics. The advantages and limitations of MIPs receive detailed examination. A comprehensive literature survey then covers various classes of illicit drugs, including opioids, stimulants, cannabinoids, and hallucinogens. Notably, the review highlights the role of computational simulations, including density functional theory (DFT), in optimizing MIP fabrication and enhancing performance. The review concludes with a discussion on the challenges related to the lack of standard parameters for selectivity, the need for robust characterization methods, and the pros and cons of using nanomaterials in MIPs. Recommendations for resolving these issues and potential future developments aimed at broadening the application scope in relevant fields are presented. Overall, this review serves as a valuable resource for researchers involved in the development and application of illicit drug detection technologies using molecularly imprinted polymers.

455

News (Medical) associated with Cannabinoids

13 Jun 2025

·www.inmedpharma.com

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA - InMed Pharmaceuticals

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Vancouver, British Columbia–(Newsfile Corp. – June 13, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed’s auditor following the acquisition of Marcum’s attest business by CBIZ CPAs P.C., with an effective resignation date of June 12, 2025 (the “Marcum Acquisition“). As a result of the Marcum Acquisition, the Company has engaged and appointed CBIZ as its new auditor for the fiscal year ending June 30, 2025. Marcum’s resignation was not due to any disagreements or reportable events related to InMed’s financial statements for the fiscal year ended June 30, 2024. The audit reports for these periods did not contain adverse opinions or disclaimers and were not qualified regarding uncertainty, audit scope, or accounting principles, except for a material weakness related to the adequacy of resources available to respond to financial reporting matters other than in the normal course of business that was previously disclosed under the heading “Item 9A. Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023. InMed further announces that its special meeting of shareholders was held today and was convened without any business being conducted, due to lack of the required quorum. Consequently, the proposed resolution to approve the potential issuance of 20% or more of the Company’s issued and outstanding common shares as of December 13, 2024 pursuant to the Standby Equity Purchase Agreement (the “SEPA“) with YA II PN, Ltd. (“Yorkville“), and pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) (the “Share Issuance Proposal“) was not formally voted on. The Company intends to assess whether it will (x) hold a subsequent special meeting of its shareholders at a later date with respect to the Share Issuance Proposal or (y) include the Share Issuance Proposal in its definitive proxy statement for the Company’s 2025 annual general meeting of shareholders. The Company also announced today that it has entered into an amendment to the SEPA, pursuant to which the Company and Yorkville agreed to amend certain of the provisions of the SEPA. Such amendment permits the Company to, at its sole discretion, temporarily suspend the use of its existing registration statement for its common shares under the SEPA (the “Registration Statement“). This suspension, known as a “Black Out Period,” may be implemented if the Company believes it is necessary to delay the disclosure of sensitive, material information or to update the Registration Statement or prospectus to ensure all information is accurate and not misleading. During any Black Out Period, Yorkville has agreed not to sell any of the Company’s common shares under the Registration Statement, although Yorkville may still sell these common shares through other legal exemptions, provided all relevant laws are followed. The Company has also committed that any Black Out Period imposed will not be more restrictive than those applied to its own directors and senior executives regarding the transfer of Company shares. Additionally, the Company will not issue any advance notices pursuant to the SEPA to Yorkville during a Black Out Period. If the Company publicly discloses the previously withheld material information during a Black Out Period, the suspension will end immediately, and Yorkville will be promptly notified. For further information on the SEPA, including important terms and conditions, please see the Company’s filings with the Securities and Exchange Commission, including the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time. About InMed InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1.604.416.0999 E: ir@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, the holding a subsequent special meeting of its shareholders at a later date with respect to the Share Issuance Proposal, the inclusion of the Share Issuance Proposal in its definitive proxy statement for the Company’s 2025 annual general meeting of shareholders, any suspension of the Company’s Registration Statement, the issuance of advance notices under the SEPA, the disclosure of withheld information and any notification the disclosure to Yorkville of the same. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, InMed’s Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255571

Executive Change

05 Jun 2025

·www.einpresswire.com

Bud & Mary’s Expands Sleep Relief Options for Iowa Medical Cannabis Patients with Launch of NUO Sleep Tablets

Medical Cannabis Sleep Solution is Formulated with Minor Cannabinoids and Backed by Research At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality.” — Lucas Nelson, Group President of Bud & Mary’s DES MOINES, IA, UNITED STATES, June 5, 2025 / EINPresswire.com / -- DES MOINES, Iowa (June 5, 2025) — Iowa medical cannabis patients can now access Bud & Mary’s NUO Sleep Tablets , a science-driven oral product that is the first of its kind in the state formulated with a blend of THC, CBD, and the minor cannabinoid CBN. Discreet, portable and precisely dosed, NUO Sleep Tablets are crafted to ease patients into a peaceful night and help them wake feeling refreshed. Scored for titrating doses, NUO Sleep Tablets serve medical cannabis patients seeking a smoke-free non-combustible, orally administered format that helps set the mood for sleep. The tablets -- free from sugar, preservatives, dyes, alcohols and artificial ingredients -- demonstrate Bud & Mary’s ongoing commitment to creating trusted, research -backed cannabis therapies. “At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality” said Lucas Nelson, Group President of Bud & Mary’s. “NUO Sleep Tablets reflect that commitment, combining precise dosing with emerging research on minor cannabinoids such as CBN. It is the next step in our work to offer Iowa patients reliable, non-combustible therapies that are grounded in science and tailored for real-world needs.” Bud & Mary’s is one of the only U.S. cannabis license holders with a DEA Schedule 1 researcher license, enabling federally authorized cannabis research. With an ISO 17025-accredited analytical laboratory, cGMP/GACP-certified production, and multiple active clinical studies, the company sets a national standard for cannabis innovation, scientific rigor, and product safety. “Sleep is one of our most fundamental biological needs, yet so many people struggle to get consistent, uninterrupted sleep,” said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary’s. “Research has shown that disturbed or insufficient sleep can affect mood, cognitive performance, and overall physical health. Now, NUO Sleep Tablets offer Iowa patients a reliable, science-backed option to assist them in obtaining a peaceful, uninterrupted night’s sleep.” As part of Bud & Mary’s dedication to researching how cannabis-based therapeutics can transform lives, the company is currently conducting a sleep-focused clinical trial with the University of Iowa, studying the effects of a patented cannabinoid-based therapeutic intradermal gel designed to improve sleep among individuals aged 50 or older with diagnosed sleep disturbances. Iowa medical cannabis patients with valid prescriptions can find NUO Sleep Tablets in licensed dispensaries across the state in 10-count and 30-count bottles. Patients can locate Iowa dispensaries that offer NUO Sleep Tablets in the store locator at this link. Product images are available at this link. Iowans seeking more information on obtaining a medical cannabis card can visit BudMary.com/IA/GetACard. For more information or to schedule an interview, please contact Irene Ancheta at 310-804-5493 or irene@themaverickpr.com. Bud & Mary’s: Crafted for You, Powered by Science. At Bud & Mary’s, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary’s products meet the highest standards of safety, consistency, and excellence. As we’ve pushed boundaries of cannabis innovation and expanded our offerings into Colorado, Michigan, Iowa, and Missouri, we’ve remained true to our family-owned and operated roots and people-focused values. For more information, visit BudMary.com. Continue the conversation on Facebook, Instagram, X, LinkedIn and TikTok. # # # Irene Ancheta Maverick Public Relations +1 310-804-5493 email us here Visit us on social media: LinkedIn Instagram Facebook TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

04 Jun 2025

·www.globenewswire.com

Revive Therapeutics Advances with Next-Generation Bucillamine Development

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders. Strategic Development Targeting High-Value Opportunities Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation. Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment. Strong Partnerships and Ongoing Research Driving Growth Revive is committed to fostering strong pharmaceutical and government collaborations to accelerate New Bucillamine's clinical and commercial development. Currently, the company is working with Defence R&D Canada – Suffield Research Centre (DRDC), part of the Canadian Department of National Defence, on a study evaluating Bucillamine for nerve agent exposure. Positive results, expected by June 2025, could pave the way for human clinical trials in the second half of 2025 and subsequent FDA and Health Canada approvals. The potential applications of Bucillamine extend to traumatic brain injury and viral infections, further expanding its market potential and long-term value for investors. Revive also reports that it is continuing to work with LTS Lohmann Therapie-System AG to settle the previously announced arbitration award. About Revive Therapeutics Ltd. Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com. For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.

Orphan DrugFast Track

100 Deals associated with Cannabinoids

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 1	United States	Cannabis Bioscience International Holdings, Inc.	20 Mar 2024
Dermatitis, Atopic	Clinical	Netherlands	Incannex Healthcare, Inc.	17 Apr 2023
Psoriasis	Clinical	Netherlands	Incannex Healthcare, Inc.	17 Apr 2023
Vitiligo	Clinical	Netherlands	Incannex Healthcare, Inc.	17 Apr 2023
Alzheimer Disease	IND Approval	Italy	Avextra Pharma GmbH	08 Oct 2024
Amyotrophic Lateral Sclerosis	IND Approval	Italy	Avextra Pharma GmbH	08 Oct 2024
Parkinson Disease	IND Approval	Italy	Avextra Pharma GmbH	08 Oct 2024
Epilepsy	Preclinical	Canada	Shackelford Pharma, Inc.	15 Jun 2025
Cancer Pain	Preclinical	Canada	Andira Medicine, Inc.	21 Jan 2025
Brain Cancer	Preclinical	Australia	Telethon Kids Institute	24 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CRD42023479375 (ESMO2024)	Not Applicable	Cancer Pain	-	Cannabinoids	ghkzwpvhbn(livlbjpgww) = hkhunabcqk cgkcebkpjd (hxrmhfmuua, -0.65 to 0.75) View more	Positive	15 Sep 2024
EAN2024	Not Applicable	Asphyxia Neonatorum	-	URB447 + TH	uksorbtqvq(afnaktitfb) = ziuuodideh ewjzcjymri (mhrrkuhoyg ) View more	-	28 Jun 2024
				TH + URB447	uksorbtqvq(afnaktitfb) = oifcbeofes ewjzcjymri (mhrrkuhoyg ) View more
NCT03782402 (CTgov)	Phase 2	Peripheral Nerve Injuries \| Peripheral Nervous System Diseases \| Sensory neuropathy	12	Cannabinoids (Placebo Cannabinoids)	jirjzxtwcy(gfukjlcxxl) = lcszfzduqj bdclwyqwob (noqgjkfoqz, 1.5) View more	-	26 Jan 2023
				Cannabinoids (Cannabinoids (THC and CBD))	pgivlxonfi(auxwffvngd) = ysajulydht qsuawbtzmf (jvccoaokkb, arobcemnjf - ywrxdbjbld) View more
EULAR2022	Not Applicable	Arthritis, Psoriatic	-	Cannabinoid (Rheumatoid Arthritis patients using cannabis)	kdzsqxgadw(caqaouncre) = 17.5% of patients with RA using cannabinoids reported side effects not leading to cessation pcnuuqpojx (pnnxergmka )	-	01 Jun 2022
ISC2022	Not Applicable	Ischemic stroke cannabinoid positive	256	Cannabinoid positive	fuxdgstazv(yriasatiov) = gmdtbgikwe hdogrjwqqn (wnfaktudlo )	-	01 Feb 2022
				Cannabinoid negative	fuxdgstazv(yriasatiov) = gsaxcvnzlk hdogrjwqqn (wnfaktudlo )
ASN2020	Not Applicable	Kidney Tubular Necrosis, Acute	-	Synthetic cannabinoids (SC)	xkmoqosqlv(kesuqudins) = A renal biopsy showed acute tubular injury with tubular dilatation, cytoplasmic simplification and vacuolization (image) looehbrgve (ckofnonpyo ) View more	-	19 Oct 2020
SNMMI2020	Not Applicable	Functional disorder	-	Regular users of legal marijuana	lfsbmhfflv(mubidotofy) = raghfcocfg picquhgjer (ydfcxtwwar )	-	15 May 2020
SFN2017	Not Applicable	Cognitive Dysfunction	-	N-Methyl-Pyrulol(NMP)	wixlqxuezc(zwjlowrfnp) = significant change in the learning process kaoavtwlih (koyetazjwo ) View more	-	12 Nov 2017
EAN2017	Not Applicable	Cluster Headache \| Migraine Disorders	-	THC+CBD 200 mg/day	qcrpwilaky(rwernzppeu) = gstywtmjbj wogpymfojk (qslcqrrurq ) View more	Positive	13 Jul 2017
				Amitriptyline 25mg/day	nvoerlafyn(agugknmhfu) = drhxpuhyky bzowxhcfxp (euswyvmeiq ) View more
ISRCTN62942668 (CUPID, Pubmed \| Health Technol Assess)	Phase 3	Brain Diseases \| Multiple Sclerosis	498	Δ(9)-tetrahydrocannabinol (Δ(9)-THC)	zccvyeccpn(qdfczlqsty): hazard ratio = 0.92 (95% CI, 0.68 - 1.23)	-	01 Feb 2015
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cannabinoids

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation